Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 35, Issue 2, 2015, Pages 230-234

  Meng, Nan ^a   Gao, Xiao ^a   Yan, Wei ^a   Wang, Mi ^a   Liu, Ping ^a   Lu, Xiao Dan ^a   Zhang, Shu Juan ^a   Lu, Ya Qi ^a   Tang, Wang Xian ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chronic hepatitis B; Interferon ; Interleukin 10; Liver cirrhosis; Telbivudine

Indexed keywords

ANTIVIRUS AGENT; TELBIVUDINE; THYMIDINE;

ADULT; AGED; ANALOGS AND DERIVATIVES; FEMALE; HEPATITIS B, CHRONIC; HUMAN; IMMUNOLOGY; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; THYMIDINE;

EID: 84928340724     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-015-1416-3     Document Type: Article

References (39)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 2004,11(2):97–107
2. Luo Z, Xie Y, Deng M, et al. Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Eur J Gastroenterol Hepatol, 2011,23(8):695–700
3. Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol, 2011,21(6):401–416
4. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis, 2005,25(Suppl 1):3–8
5. Zhu XF, Lu LX, Wang Y, et al. Effect and predictive elements for 52 weeks’ telbivudine treatment on naive HBeAg positive chronic hepatitis B. Hepat Mon, 2011,11(12):980–985
6. Pollicino T, Bellinghieri L, Restuccia A, et al. Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha. Virology. 2013,444(1–2):317–328
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001,34(6):1225–1241
8. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis, 2002,2(1):43–50
9. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis, 2002,2(7):395–403
10. Kondo Y, Asabe S, Kobayashi K, et al. Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity. J Med Virol, 2004,4(3):425–433
11. Feng H, Zhang J, Li X, et al. HBX-mediated migration of HBV-replicating HepG2 cells: insights on development of hepatocellular carcinoma. J Biomed Biotechnol, 2009, 2009: 930268
12. Gane EJ, Wang Y, Liaw YF, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int, 2011,31(5):676–684
13. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007,20;357(25):2576–2588
14. Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther, 2009,14(1):13–22
15. Phillips MG, Preedy VR, Hughes RD. Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy? Eur J Gastroenterol Hepatol, 2003,15(9):941–944
16. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology, 2000,32(3):477–481
17. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet, 1986,1(8480):523–525
18. Nord HJ. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques—a review. Gastrointest Endosc, 1982,28(2):102–104
19. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol, 1986,2(2):165–173
20. Cadranel JF, Mathurin P. Prothrombin index decrease: a useful and reliable marker of extensive fibrosis? Eur J Gastroenterol Hepatol, 2002,14(10):1057–1059
21. Croquet V, Vuillemin E, Ternisien C, et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol, 2002,14(10):1133–1141
22. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology, 1997,113(5):1609–1616
23. Plevris JN, Haydon GH, Simpson KJ, et al. Serum hyaluronan—a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol, 2000,12(10):1121–1127
24. Guechot J, Poupon RE, Giral P, et al. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol, 1994,20(3):388–393
25. Rauch I, Muller M, Decker T. The regulation of inflammation by interferons and their STATs. JAKSTAT, 2013,2(1):e23820
26. Bonorino P, Ramzan M, Camous X, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol, 2009,51(3):458–467
27. Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med, 2007,204(3):667–680
28. Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology, 2009,137(3):1151–1160, 60 e1-e7
29. Zhang Z, Zhang S, Zou Z, et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology, 2011,53(1):73–85
30. Jiang Y, Ma Z, Xin G, et al. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm, 2010,2010: 143026
31. Gaeta GB, Stornaiuolo G. Therapy of chronic hepatitis B: focus on telbivudine. Dig Liver Dis, 2007,39(Suppl 3):S372–S378
32. Das A, Maini MK. Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis, 2010,28(1):126–132
33. Zheng Y, Huang Z, Chen X, et al. Effects of telbivudine treatment on the circulating CD4(+) T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm, 2012,2012:789859
34. Shi TD, Zhang JM, Wang XF, et al. Effects of antiviral therapy with telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clin Exp Med, 2012,12(2):105–113
35. Zhao J, Li Y, Jin L, et al. Natural killer cells are characterized by the concomitantly increased interferon-gamma and cytotoxicity in acute resolved hepatitis B patients. PLoS One, 2012,7(11):e49135
36. Alatrakchi N, Koziel M. Regulatory T cells and viral liver disease. J Viral Hepat, 2009,16(4):223–229
37. Cottrez F, Groux H. Specialization in tolerance: innate CD(4+)CD(25+) versus acquired TR1 and TH3 regulatory T cells. Transplantation, 2004,77(1 Suppl):S12–S15
38. Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology, 2005,41(4):771–778
39. Nan XP, Zhang Y, Yu HT, et al. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. Viral Immunol, 2012,25(1):21–8